Publications by authors named "S Handzhiev"
What Is This Summary About?: This is a summary of a phase 2 clinical study called DeLLphi-301. The study looked at how effective and safe a medicine called tarlatamab was in participants with small cell lung cancer (SCLC). Participants previously received at least two other treatments for their SCLC.
View Article and Find Full Text PDFArticle Synopsis
- Tarlatamab is a bispecific T-cell engager immunotherapy that showed promising results in a phase 1 trial for patients with previously treated small-cell lung cancer.
- In a phase 2 trial involving 220 patients, tarlatamab was administered intravenously every 2 weeks at doses of 10 mg or 100 mg, with an objective response rate of 40% and 32% respectively.
- The study found that common side effects included cytokine-release syndrome, decreased appetite, and fever, with overall survival rates at 9 months being 68% for the 10-mg group and 66% for the 100-mg group.
Article Synopsis
- Tuberculosis (TB) remains a significant global health issue, with misdiagnosis contributing to its high mortality rate, highlighting the need for better diagnostic tests.
- A new molecular test called T-Track TB was evaluated and shown to have a sensitivity of 94.9% and specificity of 93.8%, outperforming the existing QuantiFERON-TB Gold Plus test which had a sensitivity of 84.3%.
- The T-Track TB test demonstrated reliable performance, correctly classifying the majority of active TB cases compared to non-TB controls, indicating its potential as a superior diagnostic tool for TB.
Lung involvement is the most frequent cause of death in patients with systemic sclerosis (SSc). As lung involvement is frequently asymptomatic, the current recommendation is to carry out thoracic computed tomography (CT) in all patients newly diagnosed with SSc. There is currently disagreement on how patients with SSc for whom no lung involvement was found at the time of diagnosis, should be followed up.
View Article and Find Full Text PDFThe Austrian Society of Pneumology (ASP) launched a first statement on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in May 2020, at a time when in Austria 285 people had died from this disease and vaccinations were not available. Lockdown and social distancing were the only available measures to prevent more infections and the breakdown of the health system. Meanwhile, in Austria over 13,000 patients have died in association with a SARS-CoV‑2 infection and coronavirus disease 2019 (COVID-19) was among the most common causes of death; however, SARS-CoV‑2 has been mutating all the time and currently, most patients have been affected by the delta variant where the vaccination is very effective but the omicron variant is rapidly rising and becoming predominant.
View Article and Find Full Text PDF